Multi-target drugs can better address the cascade of events involved in oxidative stress and the reduction in cholinergic transmission that occur in Alzheimer’s disease than cholinesterase inhibitors alone. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.